Dashboard
High Management Efficiency with a high ROE of 21.60%
Company has a low Debt to Equity ratio (avg) at times
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 21.60%
With a growth in Operating Profit of 68.95%, the company declared Very Positive results in Jun 25
With ROE of -53.38%, it has a risky valuation with a 10.89 Price to Book Value
Stock DNA
Software Products
USD 4,093 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.15
-36.43%
10.02
Total Returns (Price + Dividend) 
Cellebrite DI Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Cellebrite DI Ltd. Experiences Revision in Its Stock Evaluation Amidst Competitive Pressures
Cellebrite DI Ltd., a small-cap software company, is experiencing significant financial challenges, evidenced by a negative return on equity and high valuation ratios compared to peers. Its stock has declined notably this year, highlighting competitive pressures in the software products sector and difficulties in sustaining market position.
Read MoreIs Cellebrite DI Ltd. overvalued or undervalued?
As of 14 November 2025, the valuation grade for Cellebrite DI Ltd. moved from fair to attractive, indicating a more favorable outlook for the company. Based on the available metrics, Cellebrite appears to be undervalued, particularly given its Price to Book Value of 10.89 and an EV to EBITDA ratio of 50.27, which, while high, suggests potential growth relative to its current valuation. The EV to Sales ratio stands at 8.48, further supporting the notion that the company may be undervalued compared to its peers. In comparison to its industry, Cellebrite's P/E ratio is not applicable due to its loss-making status, but it is noteworthy that Clearwater Analytics Holdings, Inc. has a P/E of 12.49, while SolarWinds Corp. shows a P/E of 25.03, highlighting the disparity in valuation among peers. Although specific return data for Cellebrite is not available, the overall market sentiment reflected in the S&P 500 sug...
Read More
Cellebrite DI Ltd. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Cellebrite DI Ltd., a small-cap software company, has faced financial challenges, reporting a high price-to-book value and significant losses. Compared to peers, its valuation is less favorable, with mixed stock performance and a year-to-date return contrasting sharply with broader market gains. Ongoing volatility characterizes its current market position.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Strategic Entities
Held in 39 Schemes (7.67%)
Held by 96 Foreign Institutions (17.37%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 18.39% vs 24.77% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 181.93% vs 26.32% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 23.41% vs 20.10% in Dec 2023
YoY Growth in year ended Dec 2024 is -248.95% vs -169.85% in Dec 2023






